MRSN RSI Chart
Last 7 days
0.7%
Last 30 days
-22.4%
Last 90 days
-28.2%
Trailing 12 Months
-63.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 38.3M | 0 | 0 | 0 |
2023 | 32.3M | 38.7M | 40.8M | 36.9M |
2022 | 4.5M | 8.2M | 11.9M | 26.6M |
2020 | 0 | 28.4M | 14.6M | 828.0K |
2019 | 48.6M | 44.6M | 43.3M | 42.1M |
2018 | 16.3M | 16.8M | 12.7M | 10.6M |
2017 | 25.8M | 23.3M | 26.3M | 17.5M |
2016 | 14.1M | 17.8M | 21.5M | 25.2M |
2015 | 0 | 0 | 0 | 10.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 16, 2024 | lowinger timothy b | sold | -28,208 | 2.71 | -10,409 | svp, chief sci.&tech. officer |
Jan 16, 2024 | misra tushar | sold | -9,097 | 2.71 | -3,357 | svp, chief manuf. officer |
Jan 16, 2024 | deschuytner brian | sold | -25,276 | 2.71 | -9,327 | svp, coo & cfo |
Jan 16, 2024 | bala mohan | sold | -9,298 | 2.71 | -3,431 | svp, chief development officer |
Jan 16, 2024 | mandelia ashish | sold | -13,617 | 2.71 | -5,025 | vp, chief accounting officer |
Jan 16, 2024 | protopapas anna | sold | -79,671 | 2.71 | -29,399 | - |
Jan 16, 2024 | carvajal alejandra | sold | -11,872 | 2.71 | -4,381 | svp, chief legal officer |
Jan 15, 2024 | protopapas anna | acquired | - | - | 38,958 | - |
Jan 15, 2024 | lowinger timothy b | acquired | - | - | 15,208 | svp, chief sci.&tech. officer |
Jan 15, 2024 | mandelia ashish | acquired | - | - | 5,352 | vp, chief accounting officer |
Which funds bought or sold MRSN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -0.11 | 799,661 | 1,660,440 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.93 | 7,592 | 49,930 | -% |
May 15, 2024 | STATE STREET CORP | added | 136 | 19,224,300 | 24,628,500 | -% |
May 15, 2024 | WELLINGTON MANAGEMENT GROUP LLP | new | - | 2,395,090 | 2,395,090 | -% |
May 15, 2024 | DEUTSCHE BANK AG\ | added | 39.15 | 4,458,960 | 7,101,980 | -% |
May 15, 2024 | BARCLAYS PLC | added | 169 | 1,481,000 | 1,833,000 | -% |
May 15, 2024 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | new | - | 257,501 | 257,501 | -% |
May 15, 2024 | AQR CAPITAL MANAGEMENT LLC | sold off | -100 | -73,217 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 29.31 | 562,854 | 938,842 | -% |
May 15, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 6.62 | 185,000 | 359,000 | -% |
Unveiling Mersana Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Mersana Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Mersana Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | -13.6% | 9,245 | 10,701 | 7,698 | 10,654 | 7,802 | 14,688 | 5,573 | 4,284 | 2,036 | 11.00 | 21.00 | 32.00 | 42.00 | 844 | 202 | 41,035 | 1,189 | 2,151 | 4,191 | 3,064 | 3,261 |
Operating Expenses | -5.9% | 30,246 | 32,128 | 51,639 | 67,155 | 65,603 | 60,514 | 65,212 | 56,034 | 48,588 | 28,772 | 22,427 | 20,584 | 16,642 | 18,137 | 17,958 | 19,586 | 23,968 | 19,560 | 16,894 | - | - |
S&GA Expenses | -100.0% | - | 10,134 | 12,894 | 18,187 | 18,328 | 14,805 | 14,573 | 14,803 | 12,782 | 5,914 | 5,881 | 5,171 | 4,212 | 4,436 | 4,192 | 4,443 | 4,152 | 4,380 | 4,231 | 3,571 | - |
R&D Expenses | -13.1% | 18,686 | 21,495 | 30,531 | 48,968 | 47,275 | 45,709 | 50,639 | 41,231 | 35,806 | 22,858 | 16,546 | 15,413 | 12,430 | 13,701 | 13,766 | 15,143 | 19,816 | 15,180 | 12,663 | - | - |
Interest Expenses | -4.4% | 1,002 | 1,048 | 1,017 | 1,025 | 983 | 964 | 880 | 760 | 724 | 92.00 | 92.00 | 87.00 | 87.00 | 107 | 40.00 | - | - | - | - | - | - |
Net Income | 1.2% | -19,306 | -19,544 | -41,656 | -54,307 | -56,163 | -44,918 | -59,811 | -52,219 | -47,258 | -28,844 | -22,489 | -19,786 | -16,246 | -16,792 | -17,071 | 21,901 | -22,431 | -17,069 | -12,354 | - | - |
Net Income Margin | 24.4% | -3.52* | -4.66* | -4.82* | -5.56* | -6.59* | -7.68* | -17.49* | -23.61* | -40.40* | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -1.4% | -32,789 | -32,348 | -46,553 | -62,233 | -29,916 | -52,014 | 54,171 | -45,433 | -8,284 | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -12.2% | 198 | 226 | 263 | 311 | 296 | 334 | 315 | 252 | 258 | 206 | 218 | 254 | 248 | 273 | 290 | 311 | 96.00 | 108 | 122 | 139 | 149 |
Current Assets | -12.4% | 188 | 214 | 250 | 297 | 282 | 319 | 300 | 237 | 241 | 189 | 199 | 233 | 232 | 259 | 275 | 295 | 80.00 | 101 | 115 | 132 | 141 |
Cash Equivalents | -56.7% | 76.00 | 175 | 186 | 129 | 123 | 129 | 184 | 135 | 230 | 178 | 192 | 227 | 228 | 255 | 271 | 288 | 60.00 | 63.00 | 58.00 | 116 | 137 |
Net PPE | - | - | - | - | - | - | 4.00 | - | - | - | 2.00 | - | - | - | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 |
Liabilities | -9.9% | 170 | 189 | 211 | 221 | 232 | 242 | 225 | 118 | 118 | 84.00 | 62.00 | 58.00 | 50.00 | 45.00 | 37.00 | 37.00 | 33.00 | 29.00 | 29.00 | 31.00 | 25.00 |
Current Liabilities | -16.1% | 53.00 | 64.00 | 68.00 | 75.00 | 83.00 | 92.00 | 89.00 | 71.00 | 56.00 | 48.00 | 44.00 | 40.00 | 35.00 | 30.00 | 21.00 | 22.00 | 17.00 | 24.00 | 22.00 | 24.00 | 23.00 |
Short Term Borrowings | -100.0% | - | 2.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt | -14.5% | 20.00 | 23.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 3.00 | 4.00 | 4.00 | 5.00 | 5.00 | - |
LT Debt, Current | 150.0% | 5.00 | 2.00 | - | - | - | - | - | - | - | - | - | 0.00 | - | - | - | 2.00 | 1.00 | 1.00 | 0.00 | - | - |
LT Debt, Non Current | -100.0% | - | 23.00 | - | - | - | 25.00 | - | - | - | 25.00 | - | - | - | 5.00 | 5.00 | 3.00 | 4.00 | 4.00 | 5.00 | 5.00 | - |
Shareholder's Equity | -24.2% | 28.00 | 37.00 | 52.00 | 90.00 | 64.00 | 92.00 | 90.00 | 134 | 141 | 122 | 156 | 196 | 198 | 228 | 253 | 274 | 63.00 | 78.00 | 93.00 | 109 | 124 |
Retained Earnings | -2.3% | -845 | -826 | -806 | -765 | -710 | -654 | -609 | -549 | -497 | -450 | -401 | -356 | -315 | -280 | -251 | -229 | -209 | -192 | -176 | -159 | -142 |
Additional Paid-In Capital | 1.2% | 874 | 863 | 859 | 855 | 775 | 747 | 700 | 684 | 638 | 572 | 557 | 552 | 513 | 508 | 505 | 503 | 272 | 271 | 269 | 268 | 266 |
Shares Outstanding | 1.4% | 122 | 121 | 121 | 120 | 109 | 105 | 91.00 | 96.00 | 80.00 | 71.00 | 70.00 | 69.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 364 | - | - | - | 403 | - | - | - | 800 | - | - | - | 1,148 | - | - | - | 164 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -2.2% | -32,657 | -31,962 | -46,081 | -61,834 | -29,005 | -51,229 | 54,597 | -44,776 | -7,955 | -42,400 | -36,098 | -34,468 | -27,022 | -17,319 | -20,196 | -15,935 | -21,246 | -12,576 | -16,284 | -14,197 | -24,687 |
Share Based Compensation | 14.1% | 4,660 | 4,085 | 4,001 | 6,643 | 6,407 | 5,314 | 5,375 | 5,348 | 5,485 | 4,860 | 4,928 | 4,582 | 4,039 | 1,989 | 1,918 | 1,656 | 1,609 | 1,262 | 1,285 | 1,161 | 1,164 |
Cashflow From Investing | -460.1% | -72,547 | 20,148 | 103,778 | -5,439 | 1,396 | -45,426 | -16,491 | -90,470 | -329 | -155 | -46.00 | -333 | -114 | -188 | 2,805 | 14,975 | 19,435 | 16,500 | -41,768 | -12,153 | 10,128 |
Cashflow From Financing | 6235.9% | 5,829 | 92.00 | -146 | 73,180 | 21,549 | 41,458 | 10,638 | 40,527 | 60,394 | 28,795 | 463 | 33,916 | 472 | 1,665 | -49.00 | 228,886 | -90.00 | 231 | -8.00 | 5,277 | 92,204 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Collaboration revenue | $ 9,245 | $ 7,802 |
Operating expenses: | ||
Research and development | 18,686 | 47,275 |
General and administrative | 11,560 | 18,328 |
Total operating expenses | 30,246 | 65,603 |
Other income (expense): | ||
Interest income | 2,697 | 2,621 |
Interest expense | (1,002) | (983) |
Total other income, net | 1,695 | 1,638 |
Net loss | (19,306) | (56,163) |
Unrealized (loss) gain on marketable securities | (101) | 164 |
Comprehensive loss | (19,407) | (55,999) |
Net loss attributable to common stockholders — basic | (19,306) | (56,163) |
Net loss attributable to common stockholders — diluted | $ (19,306) | $ (56,163) |
Net loss per share attributable to common stockholders — basic (in dollars per share) | $ (0.16) | $ (0.52) |
Net loss per share attributable to common stockholders — diluted (in dollars per share) | $ (0.16) | $ (0.52) |
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares) | 121,424,953 | 107,514,655 |
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares) | 121,424,953 | 107,514,655 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 75,186 | $ 174,561 |
Short-term marketable securities | 107,960 | 34,523 |
Prepaid expenses and other current assets | 4,392 | 4,973 |
Total current assets | 187,538 | 214,057 |
Property and equipment, net | 3,408 | 3,831 |
Operating lease right-of-use assets | 6,949 | 7,694 |
Other assets, noncurrent | 478 | 478 |
Total assets | 198,373 | 226,060 |
Current liabilities: | ||
Accounts payable | 3,086 | 7,319 |
Accrued expenses | 15,856 | 21,898 |
Deferred revenue | 25,618 | 28,147 |
Operating lease liabilities | 3,547 | 3,252 |
Short-term debt | 5,208 | 2,083 |
Other current liabilities | 91 | 938 |
Total current liabilities | 53,406 | 63,637 |
Operating lease liabilities, noncurrent | 4,224 | 5,149 |
Long-term debt, net | 20,098 | 23,148 |
Deferred revenue, noncurrent | 92,022 | 97,167 |
Other liabilities, noncurrent | 638 | 55 |
Total liabilities | 170,388 | 189,156 |
Commitments (Note 11) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Common stock, $0.0001 par value; 350,000,000 shares authorized; 122,359,130 and 120,711,745 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 12 | 12 |
Additional paid-in capital | 873,730 | 863,242 |
Accumulated other comprehensive (loss) income | (90) | 11 |
Accumulated deficit | (845,667) | (826,361) |
Total stockholders’ equity | 27,985 | 36,904 |
Total liabilities and stockholders’ equity | $ 198,373 | $ 226,060 |